Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer
Marco Moschini(Vita-Salute San Raffaele University), Andrea Gallina(San Raffaele University of Rome), David D‘Andrea(Medical University of Vienna), Luca Afferi(Universitat Autònoma de Barcelona), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Alberto Martini(The University of Texas MD Anderson Cancer Center), Renzo Colombo(University of Insubria), Andrea Salonia(Vita-Salute San Raffaele University), Philipp Baumeister(University of Lucerne), Francesco Montorsi(Vita-Salute San Raffaele University), Rafael Sanchez‐Salas(Institute Mutualiste Montsouris), Xavier Cathelineau(Institute Mutualiste Montsouris), Armando Stabile(Royal Free London NHS Foundation Trust), Giusy Burgio(Vita-Salute San Raffaele University), Agostino Mattei(Luzerner Kantonsspital), Emanuele Zaffuto(Ospedale di Circolo e Fondazione Macchi), Shahrokh F. Shariat(Universitätszahnklinik Wien), Andrea Necchi(Vita-Salute San Raffaele University), Stefania Zamboni(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Carlo Di Bona(Luzerner Kantonsspital), Livio Mordasini(University Hospital of Bern), Giorgio Gandaglia(Vita-Salute San Raffaele University)
Cited by 22
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
|European Urology|2015|688